The 10-second takeaway
For the quarter ended March 31 (Q1), AstraZeneca missed estimates on revenues and beat expectations on earnings per share.
Compared to the prior-year quarter, revenue contracted. Non-GAAP earnings per share shrank significantly. GAAP earnings per share dropped significantly.
Margins dropped across the board.
AstraZeneca logged revenue of $6.39 billion. The 15 analysts polled by S&P Capital IQ hoped for revenue of $6.54 billion on the same basis. GAAP reported sales were 13% lower than the prior-year quarter's $7.35 billion.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at $1.41. The nine earnings estimates compiled by S&P Capital IQ predicted $1.36 per share. Non-GAAP EPS of $1.41 for Q1 were 22% lower than the prior-year quarter's $1.81 per share. GAAP EPS of $0.81 for Q1 were 37% lower than the prior-year quarter's $1.28 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 80.2%, 180 basis points worse than the prior-year quarter. Operating margin was 21.9%, much worse than the prior-year quarter. Net margin was 15.8%, 650 basis points worse than the prior-year quarter. (Margins calculated in GAAP terms.)
Next quarter's average estimate for revenue is $6.26 billion. On the bottom line, the average EPS estimate is $1.26.
Next year's average estimate for revenue is $26.33 billion. The average EPS estimate is $5.28.
The stock has a five-star rating (out of five) at Motley Fool CAPS, with 46 members out of 51 rating the stock outperform, and five members rating it underperform. Among two CAPS All-Star picks (recommendations by the highest-ranked CAPS members), two give AstraZeneca a green thumbs-up, and give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on AstraZeneca is hold, with an average price target of $47.30.
Can your portfolio provide you with enough income to last through retirement? You'll need more than AstraZeneca. Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks." Click here for instant access to this free report.
- Add AstraZeneca to My Watchlist.
Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor of Motley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.